{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:03:38Z","timestamp":1782860618018,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The recent therapeutic progress in multiple myeloma (MM) has led to the introduction of novel and highly potent drug classes. Daratumumab was the first CD38-targeting antibody showing to be effective and safe in MM patients as monotherapy and in combination regimens, which led to its rapid implementation in clinical practice. Considering that treatment discontinuation for drug-related adverse events can impact patients\u2019 quality of life and outcomes, the treatment decision should consider different factors and be weighted for each patient individually. Here, we aimed to guide clinicians using daratumumab treatment for MM by addressing practical real-world considerations based on an expert panel of Portuguese hematologists. Carefully following the recommendations mentioned in daratumumab\u2019s SmPC, and of those from other drugs used in combination regimens, along with ensuring a good communication with all healthcare professionals involved, is critical to prevent any complications arising from treatment. The risk of infection should be assessed for all patients under treatment with daratumumab and patients should be educated on the potential adverse events. Recommendations on prophylaxis and vaccination should be considered to avoid infections, and delays in the planned therapeutic schedule may be required to prevent adverse consequences of hematological toxicity. Daratumumab treatment is effective and feasible in patients with renal impairment, although careful patient monitoring and a frequent communication with the Nephrology department are of the utmost importance. Sharing clinical practice plays an important role in medical education by allowing to maximize treatment efficacy and minimize its safety risks.<\/jats:p>","DOI":"10.3389\/fonc.2021.817762","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:23:48Z","timestamp":1643977428000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists"],"prefix":"10.3389","volume":"11","author":[{"given":"Catarina","family":"Geraldes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Chacim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Leal","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715572295","article-title":"Daratumumab and Its Potential in the Treatment of Multiple Myeloma: Overview of the Preclinical and Clinical Development","volume":"6","author":"Phipps","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 With Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical Efficacy of Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab Monotherapy in Patients With Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 Antibodies in Multiple Myeloma: Back to the Future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc\u03b3 Receptor-Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory Effects of CD38-Targeting Antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"B18","unstructured":"DARZALEX Summary of Product Characteristics2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113161","article-title":"Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients With Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)","volume":"132","author":"Clemens","year":"2018","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243790","article-title":"Subcutaneous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma: Part 2 of the Open-Label, Multicenter, Dose-Escalation Phase 1b Study (PAVO)","volume":"106","author":"San-Miguel","year":"2021","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (COLUMBA): A Multicentre, Open-Label, Non-Inferiority, Randomised, Phase 3 Trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I Manage the Toxicities of Myeloma Drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment Options for Relapsed and Refractory Multiple Myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0443-0","article-title":"Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies","volume":"13","author":"McCullough","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2017-0328","article-title":"EMA Review of Daratumumab for the Treatment of Adult Patients With Multiple Myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5630.5630","article-title":"Daratumumab Interferes With Flow Cytometric Evaluation of Multiple Myeloma","volume":"128","author":"Perincheri","year":"2016","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin Prophylaxis in Patients With Newly Diagnosed Myeloma (TEAMM): A Multicentre, Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic Prophylaxis for Patients With Newly Diagnosed Multiple Myeloma: Systematic Review and Meta-Analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1083858","article-title":"Prevention of Viral Infections in Patients With Multiple Myeloma: The Role of Antiviral Prophylaxis and Immunization","volume":"13","author":"Teh","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cld.883","article-title":"Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4441-8","article-title":"Epidemiology and Treatment of Invasive Fungal Diseases in Patients With Multiple Myeloma: Findings From a Multicenter Prospective Study From China","volume":"37","author":"Liu","year":"2016","journal-title":"Tumour Biol"},{"key":"B34","unstructured":"Recomenda\u00e7\u00e3o Sobre Utiliza\u00e7\u00e3o De Imunoglobulina Humana Normal2020"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of Daratumumab on Normal Plasma Cells, Polyclonal Immunoglobulin Levels, and Vaccination Responses in Extensively Pre-Treated Multiple Myeloma Patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"key":"B36","unstructured":"Recomendaciones De Vacunaci\u00f3n Covid-19 En El Paciente Hematol\u00f3gico2021"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25764","article-title":"Treatment and Disease-Related Complications in Multiple Myeloma: Implications for Survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"Am J Hematol"},{"key":"B38","unstructured":"BaskerN\n          NHS - Chemotherapy Protocol Myeloma - Daratumumab V 1.22018"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.131","article-title":"Pathogenesis and Treatment of Renal Failure in Multiple Myeloma","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in Renal Function and Its Impact on Survival in Patients With Newly Diagnosed Multiple Myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17412","article-title":"Safety and Efficacy of Daratumumab in Patients With Multiple Myeloma and Severe Renal Failure","volume":"193","author":"Kuzume","year":"2021","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191122","article-title":"Safety and Efficacy of Daratumumab in Dialysis-Dependent Renal Failure Secondary to Multiple Myeloma","volume":"103","author":"Rocchi","year":"2018","journal-title":"Haematologica"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.817762\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T12:23:51Z","timestamp":1643977431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.817762\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":42,"alternative-id":["10.3389\/fonc.2021.817762"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.817762","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"817762"}}